Verici Dx plc
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Sara jane Barrington
- Full Time Employees
- 19
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- Avon House Penarth United Kingdom CF64 2EZ
- IPO Date
- May 27, 2022
- Website
- vericidx.com
- Similar Companies
- Business
- Verici Dx plc operates as an immuno-diagnostics innovator, concentrating its efforts within the kidney transplantation field. The company is actively developing advanced prognostic and diagnostic solutions for individuals undergoing kidney transplants. Its product pipeline includes Clarava, a pre-transplant test designed to predict the likelihood of early acute rejection; Tuteva, a post-transplant diagnostic focusing on acute cellular rejection, including sub-clinical forms; and Protega, a liquid biopsy aimed at foreseeing the risk of fibrosis and eventual graft failure. Leveraging AI-enhanced RNA signature analysis, Verici Dx strives to deliver personalized, data-driven insights to clinicians. Established in 2020, the firm maintains its base in Penarth, United Kingdom.
CORRECTING and REPLACING Verici Dx Announces Publication Validating Pre-Transplant Gene Signature Test for Predicting Early Acute Rejection in Kidney Transplant Recipients
Verici Dx Announces Publication Validating Pre-Transplant Gene Signature Test for Predicting Early Acute Rejection in Kidney Transplant Recipients
Verici Dx rises after passing key US laboratory accreditation audit
Verici Dx climbs on 'preferred provider' deal with US healthcare network
Verici Dx plc - Special Call
Verici Dx shares jump 23% as transplant test rollout gathers pace
Verici Dx plans fresh funding round to boost US test rollout
Verici Dx soars as Tutivia tests are confirmed by Medicare
Verici Dx says its seen a significant increase in Tutivia orders
FBB Biomed Signs Agreement with Verici Dx plc to Offer Research-Use-Only “RUO” Tests to Clinicians